TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20059603

Group type: EXPERIMENTAL
Intervention: Aminosalicylates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel agents
Number of subjects: 0
Study: 18082495

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 14700

Group type: COMPARATOR
Intervention: No amiodarone (Control)
Number of subjects: 14700
Study: 16961129

Group type: EXPERIMENTAL
Intervention: GliaSite brachytherapy (60 Gy dose administered to a 1-cm depth after resection)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: GliaSite brachytherapy
Number of subjects: 71
Study: 12942656

Group type: EXPERIMENTAL
Intervention: Brief educational intervention tailored to the patient's stage of readiness to change
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple-advice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 10826241

Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Current Therapy (CT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Education and Support Group (ES)
Number of subjects: 119
Study: 8793702

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (cycling at 60-70% of maximum workload)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caloric intake restriction (4186-6279 kl/day, 16 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise combined with caloric intake restriction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control light intensity exercise
Number of subjects: 60
Study: 1607191

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream (EMLA(R))
Number of subjects: 63

Group type: COMPARATOR
Intervention: Xylocaine 1% local infiltration
Number of subjects: 63
Study: 3518661

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 70
Study: 31578055

Group type: EXPERIMENTAL
Intervention: 0.1% aroma bath salt
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.5% aroma bath salt
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1% aroma bath salt
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 29045079

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 2210

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2210
Study: 26985726

Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 372
Study: 25261599

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT) with formal home practice of at least 3 days a week
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 99
Study: 22020133

Group type: EXPERIMENTAL
Intervention: Modified Stroop task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study: 19940856

Group type: EXPERIMENTAL
Intervention: Silver alginate (Algidex) patches
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study: 18848350

Group type: EXPERIMENTAL
Intervention: Consistent bronchodilator response (BDR)
Number of subjects: 1041
Study: 16948966

Group type: EXPERIMENTAL
Intervention: Screening for hemoglobinopathies, congenital hypothyroidism, phenylketonuria, and cystic fibrosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vision screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for tuberculosis (TB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for lead toxicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual acuity testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for TB and lead
Number of subjects: 0
Study: 12540406

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20
Study: 10813108

Group type: EXPERIMENTAL
Intervention: toremifene (40 mg/day; n = 19)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: tamoxifen (20 mg/day; n = 25)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: antiestrogen group (toremifene and tamoxifen)
Number of subjects: 44
Study: 8871423

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) model
Number of subjects: 143

Group type: COMPARATOR
Intervention: Group Skills Training
Number of subjects: 143
Study: 1640148

Group type: EXPERIMENTAL
Intervention: Injection of methylprednisolone acetate plus local anaesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control injection of local anaesthetic
Number of subjects: 0
Study: 6879242

Group type: EXPERIMENTAL
Intervention: Experimental group (E-group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 0
Study: 31289885

Group type: EXPERIMENTAL
Intervention: Alcohol (low or moderate dosage)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29649992

Group type: EXPERIMENTAL
Intervention: Fast walking training
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Step activity monitoring program
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Fast walking training + step activity monitoring program
Number of subjects: 225
Study: 27067521

Group type: EXPERIMENTAL
Intervention: Endostatin (7.5 mg/m² weekly for 14 days), Paclitaxel (50 mg/m²), Carboplatin (2 mg/mL/min over 30 min) during chemoradiotherapy; followed by Endostatin (7.5 mg/m² for 14 days), Paclitaxel (150 mg/m²), Carboplatin (5 mg/mL/min every 3 weeks for 2 cycles) as consolidation treatment.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Endostatin treatment
Number of subjects: 19
Study: 24500751

Group type: EXPERIMENTAL
Intervention: Low mismatch prevalence (10%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High mismatch prevalence (50%)
Number of subjects: 0
Study: 22420935

Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation Program (R & R)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19589602

Group type: EXPERIMENTAL
Intervention: SSRIs plus supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study: 18024167

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16109248

Group type: EXPERIMENTAL
Intervention: Ambulatory smoking cessation intervention sessions (5 sessions)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard smoking cessation information)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ambulatory smoking cessation intervention
Number of subjects: 105
Study: 12075743

Group type: EXPERIMENTAL
Intervention: Alternating treatment group (A) received docetaxel 100 mg/m2 on days 1 and 43, alternating with cisplatin 100 mg/m2 on day 22 and vinorelbine 30 mg/m2 on days 22, 29, and 36.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (B) received cisplatin 80 mg/m2 on days 1, 22, and 43, and vinorelbine 30 mg/m2 once a week from day 1 to day 57.
Number of subjects: 70
Study: 9935086

Group type: EXPERIMENTAL
Intervention: 10% glycolic acid cream twice daily (n=25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream qHS and tretinoin 0.025% cream twice daily (n=25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No pretreatment (n=50, control)
Number of subjects: 100
Study: 8800850

Group type: EXPERIMENTAL
Intervention: Johnson double pad antishear device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard single pad device
Number of subjects: 10
Study: 2144207

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 264

Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 264
Study: 30702948

Group type: EXPERIMENTAL
Intervention: Yoga-based cardiac rehabilitation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (enhanced standard care)
Number of subjects: 80
Study: 28558739

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MCT group; 60-80% HRR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-intensity interval training (HIT group; 4 x 4 min at 85-95% peak HRR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MCT group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-intensity interval training (HIT group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between MCT and HIT
Number of subjects: 20
Study: 26598141

Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^5 CFU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: BCG (5×10^5 CFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^4 CFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^3 CFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTBVAC and BCG (whole blood stimulation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTBVAC and BCG (IGRA results)
Number of subjects: 36
Study: 23567001

Group type: EXPERIMENTAL
Intervention: Twice-daily insulin lispro mix 75/25 (LM75/25)
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Once-daily insulin glargine
Number of subjects: 2091
Study: 22161918

Group type: EXPERIMENTAL
Intervention: Trained cohort
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untrained cohort
Number of subjects: 33
Study: 19172535

Group type: EXPERIMENTAL
Intervention: 200 mg micronized progesterone vaginally three times per day starting in the afternoon of oocyte retrieval until the morning of embryo transfer, in addition to standard hCG luteal-phase support.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard hCG luteal-phase support only.
Number of subjects: 197
Study: 17062301

Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: AZD3582 1500 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: AZD3582 2250 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 12920841

Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 ropivacaine + 2 mg.L‐1 fentanyl (Group RF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 2 mg.L‐1 fentanyl (Group BF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 80 mg.L‐1 morphine (Group BM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: General‐epidural anesthesia and patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group EM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group M)
Number of subjects: 42
Study: 10941607

Group type: EXPERIMENTAL
Intervention: Psychological support associated with pharmacological treatment (benzodiazepine, gamma‐hydroxybutyric acid)
Number of subjects: 0
Study: 9246967

Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional colposuspension
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 1531827

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study: 3839018

Group type: EXPERIMENTAL
Intervention: Efamol treatment (prostaglandin synthesis precursor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (n = 25)
Number of subjects: 30
Study: 29705519

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist anakinra
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 26259762

Group type: EXPERIMENTAL
Intervention: Printed educational materials + patient navigation services
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Printed educational materials (control group)
Number of subjects: 1905
Study: 24115469

Group type: EXPERIMENTAL
Intervention: Psychosocial support from a specially trained nurse (INS)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Psychosocial support from a psychologist (IPS)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 168
Study: 21988960

Group type: EXPERIMENTAL
Intervention: Ledermix(®)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultracal XS(®)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 20218813

Group type: EXPERIMENTAL
Intervention: OAP protocol
Number of subjects: 119

Group type: COMPARATOR
Intervention: COMP protocol
Number of subjects: 119
Study: 18280941

Group type: EXPERIMENTAL
Intervention: Piezoosteotomy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional harvesting
Number of subjects: 13
Study: 16181747

Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI) 3 g daily for 7 to 10 days
Number of subjects: 399

Group type: COMPARATOR
Intervention: Amoxicillin (AMX) 3 g daily for 7 to 10 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Amoxicillin (AMX)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI) and Amoxicillin (AMX)
Number of subjects: 399
Study: 12097669

Group type: EXPERIMENTAL
Intervention: 8.4 micromol vitamin A plus 1.07 mmol iron [A + Fe]
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.07 mmol iron [Fe]
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 8.4 micromol vitamin A [A]
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo [Pl]
Number of subjects: 27
Study: 10433531

Group type: EXPERIMENTAL
Intervention: Pronation and flexion (PF)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Supination and flexion (SF)
Number of subjects: 135
Study: 7720443

Group type: EXPERIMENTAL
Intervention: 10-cm stapled colonic pouch low rectal anastomosis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stapled straight coloanal anastomosis
Number of subjects: 38
Study: 2039996

Group type: EXPERIMENTAL
Intervention: Nonlocalized cancer cases
Number of subjects: 103

Group type: COMPARATOR
Intervention: Localized malignancies
Number of subjects: 103
Study: 6457618

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 0
Study: 30224345

Group type: EXPERIMENTAL
Intervention: Panobinostat 40 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (A arm)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (B arm)
Number of subjects: 55

Group type: COMPARATOR
Intervention: High-dose bicalutamide (historical control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in A arm
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in B arm
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Principal A-arm grade 3 AEs
Number of subjects: 55
Study: 27896644

Group type: EXPERIMENTAL
Intervention: El Sistema music program (treatment group)
Number of subjects: 2914

Group type: COMPARATOR
Intervention: Control group (no music program)
Number of subjects: 2914
Study: 26655003

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.05 ml) 1 week before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subconjunctival normal saline (1.25 mg/0.05 ml) 1 week before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23409862

Group type: EXPERIMENTAL
Intervention: Intervention dining halls (multicomponent, point‐of‐selection marketing campaign)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Control dining halls
Number of subjects: 458
Study: 20180042

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation for 45 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: IVF group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation
Number of subjects: 43
Study: 20086314

Group type: EXPERIMENTAL
Intervention: 200 mg calcium plus 800 IU vitamin D(3)/d (Ca+VD group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 200 mg calcium/d (Ca group)
Number of subjects: 62
Study: 16101342

Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention with counselling and/or nicotine replacement therapy (NRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Number of subjects: 0
Study: 12051574

Group type: EXPERIMENTAL
Intervention: 0.5 g b.i.d. dosing of Nitazoxanide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 g b.i.d. dosing of Nitazoxanide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10086859

Group type: EXPERIMENTAL
Intervention: Moisturizer applied 3 times daily for 4 weeks on one forearm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control forearm (no moisturizer)
Number of subjects: 0
Study: 7733057

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 16
Study: 2327750

Group type: EXPERIMENTAL
Intervention: 400 mg once daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg twice daily for 5 days
Number of subjects: 0
Study: 6989699

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31540574

Group type: EXPERIMENTAL
Intervention: Fabomotizole (10 mg thrice a day)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 286
Study: 28762756

Group type: EXPERIMENTAL
Intervention: Intranasal 24 IU Oxytocin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24927031

Group type: EXPERIMENTAL
Intervention: Transcanalicular diode laser dacryocystorhinostomy (TCL‐DCR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nonoperated side (control)
Number of subjects: 42
Study: 23430709

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Higher doses of patch and oral NRT
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Inhalator to deliver oral NRT
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: NRT consumption
Number of subjects: 633
Study: 21336953

Group type: EXPERIMENTAL
Intervention: Lateral jumps
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lateral landings
Number of subjects: 10
Study: 19727679

Group type: EXPERIMENTAL
Intervention: 20 mg D-amphetamine
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 18076801

Group type: EXPERIMENTAL
Intervention: Morphine sulfate controlled-released tablet
Number of subjects: 121

Group type: COMPARATOR
Intervention: Morphine hydrochloride sustained-released tablet
Number of subjects: 121
Study: 15200750

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oxycodone controlled release (CR)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 11425818

Group type: EXPERIMENTAL
Intervention: Low stimulation IVF (LS-IVF)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard IVF (S-IVF)
Number of subjects: 283
Study: 9795874

Group type: EXPERIMENTAL
Intervention: Benefits of screening presented as relative risk reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benefits of screening presented as numbers needed to screen to save a life
Number of subjects: 0
Study: 7516641

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thymopentin + G‐CSF
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2556079

Group type: EXPERIMENTAL
Intervention: Daptomycin (1 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daptomycin (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daptomycin and Amikacin (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daptomycin (1 or 2 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vancomycin (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daptomycin and Amikacin combination
Number of subjects: 12
Study: 4154124

Group type: EXPERIMENTAL
Intervention: S.A.I.M.R. antivenom (average dose 15.2 ml)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Behringwerke antivenom (average dose 37.9 ml)
Number of subjects: 46
Study: 31230602

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study: 29069224

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 16
Study: 26142347

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysteropexy (LH)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 132
Study: 23276410

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: PRGF and Conventional surgery
Number of subjects: 63
Study: 21563035

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 microgram every second hour, total 1600 microgram)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects with no previous use of beta2‐agonists)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (asthmatics and controls)
Number of subjects: 20